Bill Rastetter

Tracked participation in 1 Atlas company, with 0 explicitly attributed leads.

1portfolio companies

2round participations

0lead positions

Oct 2023latest activity

Capital activity

Portfolio

CompanyLatest valuationFirst → latestRoundsRoleAttributed partner

ITIambic TherapeuticsScienceIambic Therapeutics (formerly Entos) is a clinical-stage life science and technology company developing…$8.4Mvaluation$476MraisedRecent roundsOversubscribed financing round (company described as >$100M) · Nov 2025$100M · Abingworth, Alexandria Venture Investments +15Series B extension (oversubscribed) · Jun 2024$50M · led by Exor Ventures, Mubadala CapitalSeries B (oversubscribed) · Oct 2023$100M · led by Abingworth, Ascenta CapitalIambic Therapeutics—Oct 2021 → Oct 20232 roundsParticipant—

DateCompanyRoundRaisedValuationRoleEvidence

Oct 03, 2023ITIambic TherapeuticsScienceIambic Therapeutics (formerly Entos) is a clinical-stage life science and technology company developing…$8.4Mvaluation$476MraisedRecent roundsOversubscribed financing round (company described as >$100M) · Nov 2025$100M · Abingworth, Alexandria Venture Investments +15Series B extension (oversubscribed) · Jun 2024$50M · led by Exor Ventures, Mubadala CapitalSeries B (oversubscribed) · Oct 2023$100M · led by Abingworth, Ascenta CapitalIambic TherapeuticsSeries B (oversubscribed)$100M—Participant

Source ↗

Oct 03, 2021ITIambic TherapeuticsScienceIambic Therapeutics (formerly Entos) is a clinical-stage life science and technology company developing…$8.4Mvaluation$476MraisedRecent roundsOversubscribed financing round (company described as >$100M) · Nov 2025$100M · Abingworth, Alexandria Venture Investments +15Series B extension (oversubscribed) · Jun 2024$50M · led by Exor Ventures, Mubadala CapitalSeries B (oversubscribed) · Oct 2023$100M · led by Abingworth, Ascenta CapitalIambic TherapeuticsSeries B$100M—Participant

Source ↗

DateCompanyRoundRaisedValuationRoleEvidence

Source ↗